|
|
|
New York Securities Industry Litigation Law Firm
Law Firm News/New York |
2012/02/06 09:57
|
We have an extensive track record of successful engagements that can be matched by few firms of our size. With a dedicated focus on the financial services arena, we represent broker-dealers, registered representatives and other industry participants in a broad spectrum of securities disputes in court and in FINRA arbitration.
Our principal attorney has handled approximately 200 FINRA arbitrations and has a lengthy record of success in those matters that have been tried to verdict. Our clients have entrusted us to litigate sales practice disputes of virtually every type, encompassing a wide variety of products. As a small law firm, we are free from the conflicts faced by many larger law firms. This flexibility enables us to represent investors with substantial claims, along with claims in which one broker-dealer is adverse to another. Our founding partner is a certified arbitrator for FINRA and the NFA and formerly served as in-house counsel for an NYSE-member broker-dealer. This in-the-trenches experience provides unique insight to our advocacy.
Herskovits Law is a New York based law firm acknowledged as one of the premier firms in the areas of securities industry litigation and financial services arena. Founded by principal attorney, Robert L. Herskovits, the firm continues fighting for the rights of broker-dealers, registered representatives and other industry participants of security disputes. Herskovits Law has recovered 200 FINRA arbirtrations and has a lengthy record of success.
Visit www.herskovitslaw.com to see more. |
|
|
|
|
|
|
Las Vegas Product Liability Attorney - Luis A. Ayon
Attorney News |
2012/02/06 09:57
|
Las Vegas Product Liability Attorney - Luis A. Ayon
Luis has significant litigation experience in Nevada's state and federal courts. He focuses his practice on complex commercial litigation and contested and adversarial matters in bankruptcy court, real estate litigation and financial institutions litigation.
Prior to joining the firm, Luis was an associate at an international law firm where he focused on commercial litigation as well as contested bankruptcy matters. He also served as the first law clerk for Presiding Civil Judge, the Honorable Elizabeth Gonzalez and worked for one of the nation's largest plaintiffs' firms where he managed a significant case load involving catastrophic brain and spinal injuries, wrongful death, product liability and insurance bad faith claims.
Luis A. Ayon is commited to providing clients with the highest level of personal service. His dedication in his work focusing on all phases of litigation from obtaining fast pre-litigation results to handling cases through trial and appeal has given him extensive experience. His experience can rest assure that all cases will be handled by skilled professionals.Contact Maier Gutierrez Ayon PLLC.
|
|
|
|
|
|
|
Robbins Umeda LLP Announces Class Action
Securities Class Action |
2012/02/06 09:56
|
Shareholder rights firm Robbins Umeda LLP, announces that the firm commenced a class action lawsuit on February 3, 2012 in the U.S. District Court for the Northern District of Illinois, Eastern Division, on behalf of all persons or entities who purchased or otherwise acquired the securities of BioSante Pharmaceuticals, Inc. between February 12, 2010 and December 15, 2011 (the "Class Period"). The action is against the Company and the Company's Chief Executive Officer for violations of the Securities and Exchange Act of 1934.
BioSante Pharmaceuticals is a specialty pharmaceutical Company focused on developing products for female sexual health and oncology. Over the last decade, BioSante has been in the process of developing LibiGel, a drug designed to improve the sex drive of women suffering from female sexual dysfunction, specifically hypoactive desire disorder.
The complaint alleges that beginning on February 12, 2010, the Company, along with its Chief Executive Officer, issued a series of materially false and misleading statements to investors about LibiGel's commercial viability, effectiveness, and market potential that caused shares of BioSante to trade at artificially high prices. Specifically, it is alleged that officials at BioSante boasted that clinical data demonstrated that LibiGel had a "statistically significant" effect on female patients treated with the product, and that LibiGel was "the most clinically advanced pharmaceutical product in the U.S." Additionally, it is alleged that BioSante and its Chief Executive Officer misled investors by routinely analogizing LibiGel's market potential to the $2 billion dollar market for male erectile drugs, often comparing LibiGel to products like "Viagra, Levitra, and Cialis."
Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. Robbins Umeda LLP has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.
|
|
|
|
|
|
|
Murray Frank LLP Files Class Action
Securities Class Action |
2012/02/03 10:03
|
Murray Frank LLP has filed a class action complaint in the United States District Court for the Southern District of New York (Case No. 12 Civ. 0672) on behalf of all individuals and institutions who purchased securities of GLG Life Tech Corporation during the period between February 1, 2011 and November 13, 2011 (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, the Defendants made false and misleading statements about or knew but failed to disclose that: (1) the Company’s original equipment manufacturers were experiencing production issues that impacted the packaging and appearance quality of its products; (2) consumers were responding poorly to the Company’s AN0C and stevia products; and/or (3) the Company would not meet its earnings projections.
On October 6, 2011, GLG Life Tech issued a press release disclosing for the first time a negative outlook concerning its AN0C and stevia products. On the news, the Company’s stock price dropped by 42% from a close of $3.45 per share on October 5, 2011 to a close of $1.99 per share on October 6, 2011.
Subsequently, on November 14, 2011, the Company announced financial results for the period ending September 30, 2011. Revenue for the period was $1.7 million, versus revenue of $20.9 million for the same period in the previous year. EBITDA for the period was negative $8.8 million, versus EBITDA of $6.1 million for the same period in the previous year. Following its announcement of these disappointing results, the Company’s management declined to provide any further formal guidance on revenues, EBITDA, or capital expenditures. On the news, the Company’s stock price continued to drop, from a close of $2.32 per share on November 11, 2011 (the last trading day before the announcement) to a close of $2.01 on November 14, 2011.
If you purchased GLG Life Tech securities during the period between February 1, 2011 and November 13, 2011, you may move the Court, not later than February 13, 2012, to serve as Lead Plaintiff for the Class. A Lead Plaintiff is a representative chosen by the Court who acts on behalf of other class members in directing the litigation. You do not need to be a Lead Plaintiff to be included in the class.
www.murrayfrank.com
|
|
|
|
|
|
|
Goldman to face mortgage debt class-action lawsuit
Headline Legal News |
2012/02/02 10:03
|
Goldman Sachs Group Inc was ordered by a federal judge to face a securities class-action lawsuit accusing it of defrauding investors about a 2006 offering of securities backed by risky mortgage loans from a now-defunct lender.
U.S. District Judge Harold Baer in Manhattan certified a class-action lawsuit by investors led by the Public Employees' Retirement System of Mississippi.
These investors claimed they lost money in the GSAMP Trust 2006-S2, a $698 million offering of certificates backed by second-lien home loans made by New Century Financial Corp, a California subprime mortgage specialist that went bankrupt in 2007.
Thursday's decision is a setback for Goldman, which had sought to force investors to bring their cases individually.
Class certification lets investors pool resources, which can cut costs, and can lead to larger recoveries than if investors are forced to sue individually.
Goldman spokesman Michael Duvally declined to comment.
The bank is one of many accused by Congress, regulators and others of having fueled the nation's housing crisis and 2008 financial crisis in part by having misled investors about the quality of mortgage debt they sold.
|
|
|
|
|
|
|
 |
Investment Fraud Litigation |
|
|
|
|
Securities fraud, also known as stock fraud and investment fraud, is a practice that induces investors to make purchase or sale decisions on the basis of false information, frequently resulting in losses, in violation of the securities laws. Securities Arbitration. Generally speaking, securities fraud consists of deceptive practices in the stock and commodity markets, and occurs when investors are enticed to part with their money based on untrue statements.
|
|
|
| |
| |
| |
|
The content contained on the web site has been prepared by Securities Law News as a service to the internet community and is not intended to constitute legal advice or a substitute for consultation with a licensed legal professional in a particular case. | Affordable Law Firm Website Design by Law Promo |
|
Legal News RSS Feed
